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Weak acids such as acetic acid and N-acetyl cysteine (NAC) at pH less than their pKa can effectively eradicate
biofilms due to their ability to penetrate the biofilm matrix and the cell membrane. However, the optimum
conditions for their activity against drug resistant strains, and safety, need to be understood for their application
to treat infections or to inactivate biofilms on hard surfaces. Here, we investigate the efficacy and optimum
conditions at which weak acids can eradicate biofilms. We compared the efficacy of various mono and triprotic
weak acids such as N-acetyl cysteine (NAC), acetic acid, formic acid and citric acid, in eradicating biofilms. We
found that monoprotic weak acids/acid drugs can kill mucoid P. aeruginosa mucA biofilm bacteria provided the pH
is less than their pKa, demonstrating that the extracellular biofilm matrix does not protect the bacteria from the
activity of the weak acids. Triprotic acids, such as citric acid, kill biofilm bacteria at pH < pKa1. However, at a pH
between pKa1 and pKa2, citric acid is effective in killing the bacteria at the core of biofilm microcolonies but does
not kill the bacteria on the periphery. The efficacy of a monoprotic weak acid (NAC) and triprotic weak acid (citric
acid) were tested on biofilms formed by Klebsiella pneumoniae KP1, Pseudomonas putida OUS82, Staphylococcus
aureus 15981, P. aeruginosa DK1-NH57388A, a mucoid cystic fibrosis isolate and P. aeruginosa PA_D25, an anti-
biotic resistant strain. We showed that weak acids have a broad spectrum of activity against a wide range of
bacteria, including antibiotic resistant bacteria. Further, we showed that a weak acid drug, NAC, can kill bacteria
without being toxic to human cells, if its pH is maintained close to its pKa. Thus weak acids/weak acid drugs
target antibiotic resistant bacteria and eradicate the persister cells in biofilms which are tolerant to other con-
ventional methods of biofilm eradication.Introduction
Bacterial infection is a serious clinical challenge that is increasingly
difficult to treat with the growing prevalence of drug-resistant pathogens.
While antimicrobial resistance is a natural phenomenon, the prolifera-
tion of resistance has been accelerated by the widespread use of antibi-
otics in humans, animals and agriculture [1,2]. This is further
exacerbated by the observation that biofilm formation is generallyl Engineering, Massachusetts Inst
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4]. When growing as a biofilm, bacteria are protected by a matrix
composed of a cross-linked network of polysaccharides, nucleic acids,
proteins and other macromolecules. The biofilm matrix forms a robust
and elastic material [5–7], which the drugs that treat biofilm-related
infections need to penetrate to kill the bacteria embedded within.
Although various hypotheses have been proposed for the mechanism of
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biofilm matrix [8]. The penetration of drugs is hindered by the charges
on the different components of the matrix, with neutral molecules able to
pass through while charged molecules are prevented from penetrating
the biofilm [9–14]. For example, positively charged drugs such as
ampicillin and ciprofloxacin bind to the negatively charged matrix of
Klebsiella pneumoniae, which reduces the amount of drug that reaches the
bacteria within the biofilm, and may also allow for the pathogen to ex-
press adaptive responses [11]. Apart from reduced antibiotic penetration,
other biofilm-associated drug tolerance mechanisms include slow
growth, adaptive stress responses and the induction of biofilm specific
genes [15,16].
The antimicrobial tolerance of biofilms has also been attributed in
part to the presence of persister cells within the nutrient-deprived biofilm
interior [17–19]. For example, some antibiotics act only on bacteria that
are metabolically active and thus the metabolically inactive bacteria in
biofilms, such as persister cells, are naturally insensitive. Only colistin
and ofloxacin have been shown to be active against non-growing
Gram-negative bacteria and to date no antibiotics have been demon-
strated as active against non-growing S. aureus [20,21]. Furthermore,
bacteria throughout the biofilm have different growth kinetics. For
example, in vitro studies have shown that the bacteria in the inner-most
part of the biofilm microcolonies can be in stationary phase, which limits
antibiotic efficacy due to their slow or non-growth phenotype [18,22].
The persister cells in vivo have also been shown to have implications in
diseases. For example, Salmonella formed non-replicating persister pop-
ulations upon uptake by macrophages, and P. aeruginosa isolates from
cystic fibrosis patients produced high levels of drug tolerant persister
cells which was linked to the recalcitrance of cystic fibrosis infection [23,
24].
P. aeruginosa is an opportunistic pathogen responsible for infections in
a variety of conditions, including burn wounds and indwelling medical
devices [25] and has limited susceptibility to many antimicrobial agents.
Exposure to various antimicrobial drugs has resulted in the selection for,
and rise in prevalence of, multi-drug resistant strains of P. aeruginosa [25,
26]. The extracellular matrix of P. aeruginosa is comprised mainly of
polysaccharides such as alginate, Psl, Pel and extracellular DNA (eDNA)
[27]. K. pneumoniae, a Gram-negative opportunistic pathogen, is
commonly associated with hospital-acquired infections due to its
multi-drug resistance [28]. The resistance of K. pneumoniae to ampicillin
and ciprofloxacin has been partly attributed to slow growth phenotypes
when the pathogen forms biofilms [11,29]. The presence of capsular
polysaccharides in the matrix of K. pneumoniae also contributes to its
tolerance [30]. Pseudomonas putida is a Gram-negative bacterium and
75% of its matrix is comprised of proteins, with other major components
including polysaccharides and eDNA [31]. One of the more prevalent
drug-resistant pathogens is the Gram-positive Staphylococcus aureus,
whose extracellular matrix is largely comprised of cytoplasmic proteins
that reversibly associate with the cell surface at low pH [32,33].
Organic weak acids have been used to treat infections for thousands
of years [34], and there has been a recent resurgence of interest in the use
of weak acids to treat bacterial infections. Various modes of action of
weak acids on bacteria have been described [35], such as lipophilic
properties that allow the uncharged form of weak acids to diffuse freely
across the bacterial cell membrane into the cytoplasm until reaching an
equilibrium. The decrease in intracellular pH has been implicated in
causing growth inhibition, however, bacteria can survive at low intra-
cellular pH [34]. Another model suggests that perturbation of membrane
function may be the primary cause for the antimicrobial effect [36].
There is also evidence indicating that weak acids result in anions accu-
mulating inside the cytoplasm, which may have an osmotic effect and
alter metabolic processes within the cell [34].
Acetic acid has been shown to kill P. aeruginosa and S. aureus bacteria
and to eradicate wound infections [35,37,38]. N-acetylcysteine (NAC) is
a mucolytic agent that is an active ingredient in many ’over-the-counter’
drugs used widely for its antioxidant and free radical scavenging property2
that is considered safe and has FDA approval [39,40]. Complete eradi-
cation of a mucoid strain of P. aeruginosa biofilms with NAC was
demonstrated at pH of the drug less than its pKa [5]. The mechanism of
action for NAC was attributed to its weak acid nature, eliciting a similar
response as that of acetic acid, which penetrates the bacterial cell wall in
its undissociated state. Citric acid is a triprotic acid with three pKa values
and 40% citric acid has been shown to prevent recolonization of oral
biofilm on titanium surfaces [41] and reduced survival rate of bacteria in
Pseudomonas biofilms [42]. Monoprotic acids such as acetic acid and NAC
is known to kill bacteria at pH < pKa. However it is not clear if this
behaviour can be generalized to all weak acids. The efficacy of triprotic
acids such as citric acid across its three pKa values has not been inves-
tigated. The optimum concentrations and pH of weak acids/weak acid
drugs to treat infections and to achieve complete eradication of biofilm,
the breadth of activity as well as the cytotoxicity on human cells due to
low pH of drugs are also not well established.
Here we investigate the commonality of weak acids in eradicating
biofilms and how the efficacy varies with proticity. We employed various
monoprotic acids, such as formic acid, NAC and acetic acid, and the
triprotic acid, citric acid, across different pKa values. We also compared
the bactericidal activity of monoprotic NAC and triprotic citric acid on
biofilms with different morphology and matrix composition as well as
biofilms of medically relevant bacteria, including a mucoid cystic fibrosis
isolate and an antibiotic resistant strain. Finally, the effect of weak acids
onmammalian cells to determine the suitability of weak acids as effective
antimicrobials in conjunction with mammalian tissues was explored.
Results and discussion
Weak acids kill biofilm bacteria at pH < pKa
The efficacy of various monoprotic weak acids such as NAC, acetic
acid and formic acid on bacterial biofilms is investigated to understand
their behavioural similarities. P. aeruginosa mucAwas grown in a flow cell
with a continuous flow (flow rate of 100 μL/min) of 10% Luria-Bertani
broth (LB) at pH 6.7 as previously described [6,7]. The flow of me-
dium was stopped to administer NAC, acetic acid or formic acid at pH 3.0
(<pKa) and at pH 5 (>pKa), at a rate of 200 μL/min, using a syringe
pump for 30 min. The biofilms were treated with propidium iodide (PI)
before and after treatment to check for the presence of dead bacteria.
Experiments were also performed without staining with PI before treat-
ment to rule out any effect of the PI stain on the response of the bacteria
to weak acids. At pH> pKa, the percentages of live bacteria when treated
with NAC, acetic acid and formic acid were 86  4%, 94  3% and 99 
0.2%, respectively (Fig. 1b, c and d), which corresponds to the percent-
age of live bacteria intrinsically present in a biofilm before treatment
with any compounds. This suggests that the bacteria are not killed under
these conditions. In contrast, at pH < pKa, no live cells were detected,
even within the first few minutes of completing the treatment (Fig. 1e, f
and g). For all three compounds at pH < pKa, the bacteria in biofilms
were completely killed as determined by PI staining and the absence of
any green signal from GFP.
The percentages of live and dead bacteria were quantified using
fluorescent intensity of PI stain and GFP. After treatment with weak acids
at pH < pKa, there were no detectable live bacteria (Fig. 1i). Further-
more, no biofilm regrowth was observed after 24 h. Although PI staining
is used widely to determine the viability of bacteria, a recent study has
shown that extracellular DNA (eDNA) may interfere with the viability
estimate leading to the overestimation of the dead cell count [43]. Hence,
we also checked the number of colony forming units (CFU) of the bacteria
in the biofilms after treatment with different acids and found that the
CFU/mL was below the detection limit when treated with weak acids at
pH < pKa (Fig. 1h). This confirmed that NAC, acetic acid and formic acid
exhibited a common behaviour in which the undissociated form of weak
acids (pH< pKa) penetrate the P. aeruginosa mucA biofilmmatrix and kill
all the bacteria embedded within. This also suggests that the viability
Fig. 1. P. aeruginosa mucA biofilms treated with monoprotic weak acids at pH below their pKa values kill all of the bacteria in the biofilm. (a) GFP tagged biofilm
treated with PI stain before treatment with drugs shows only a few dead bacteria. No significant killing was observed when biofilms were treated with (b) NAC (c)
acetic acid and (d) formic acid at pH > pKa. All of the bacteria in the biofilm were killed when treated with (e) NAC (f) acetic acid and (g) formic acid at pH < pKa. (h)
CFU per mL of bacteria in biofilms after treatment with weak acids at pH 3 showed no detectable colonies. (i) The percentage of live and dead bacteria when treated
with NAC, acetic acid and formic acid at pH 5 (>pKa) and pH 3 (<pKa). (j, k) Biofilms treated with 2 mg/mL NAC at pH 3.8 and 3 kills bacteria in the biofilms only at
pH 3.
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conditions used here.
In all of the above experiments, the pH of the drug was altered by
changing the concentration of the drug. Hence to show that the killing of
bacteria is not just due to the changes in concentrations, experiments
were performed with the same concentration of NAC at different pH.
Here, the pH was changed by preparing NAC in different solvents. For
example, 2 mg/mL NAC prepared using PBS buffer and 10% LB had a pH
of 3.8 and 3 respectively. It should be noted that only 0.5 mg/mL NAC is
required to prepare a solution of pH 3.8 with 10% LB. Higher concen-
tration of NAC was required with PBS due to the buffering action of PBS.
The bacteria in biofilms were killed only when the pH of the drug was
maintained at pH 3 (Fig. 1k). Hence pH of the drug relative to its pKa is
the key factor in killing the biofilm bacteria.The biofilm killing efficacy of citric acid varies between its three pKa values
Given that the monoprotic weak acids outlined above killed biofilm
bacteria when the pH< pKa, we then tested the biofilm killing efficacy of
different concentrations of citric acid, a triprotic acid (pKa1 ¼ 3.13,
pKa2 ¼ 4.76 and pKa3 ¼ 6.41) on P. aeruginosa mucA. We observed that
GFP tagged P. aeruginosa mucA biofilms treated with citric acid at pH 3
(<pKa1) displayed no detectable live bacteria (Fig. 2a), but that citric
acid was ineffective at pH 5 (>pKa2), with 95 4% of biofilm cells being
viable (Fig. 2e). At pH levels between pKa1 and pKa2, 88  5%, 70 
10% and 10 4% of bacteria in biofilms were killed at pH 3.6, 3.8 and 4,
respectively (Fig. 2f). The CFU/mL also showed a similar trend with no
detectable CFU at pH 3, a decrease in CFU from 2.5 109 2 109 CFU/
mL to 1.8 107 1 107 CFU/mL at pH 3.7 and no change in CFU at pH3
5.6 (Fig. 2g). It should be noted that at concentrations corresponding to
pH between pKa1 and pKa2, the bacteria in the interior of the micro-
colonies were killed, while the cells on the periphery appeared to be
alive, although the percentage of these viable cells varied (Fig. 2b, c and
d).
Since the biofilm microcolonies have a metabolically active subpop-
ulation of bacteria on the periphery and dormant bacteria within the
microcolony [44], we hypothesised that citric acid at pH between pKa1
and pKa2 kills the metabolically inactive population of bacteria in bio-
films. This behaviour is similar to many of the membrane-targeting drugs
such as colistin, EDTA, SDS and chlorhexidine that specifically kill the
inactive subpopulation and do not affect the active subpopulation. The
metabolically active subpopulation of P. aeruginosa adapts to these
membrane targeting drugs through different genetic mediated de-
terminants [45,46]. The mechanism by which these drugs kill the
metabolically inactive, but not the active bacteria in biofilms is not
clearly understood.Citric acid at pH between pKa1 and pKa2 is ineffective in killing planktonic
bacteria in log phase
The above response elicited by citric acid was intriguing and we
subsequently tested the hypothesis that citric acid at pH between pKa1
and pKa2 would be effective in killing the dormant but not the meta-
bolically active bacteria. This hypothesis was tested using P. aeruginosa
mucA planktonic cultures. The number of colony forming units (CFU/mL)
were recorded after 0, 1 and 3 h of growth, post exposure to varying
concentrations of NAC and citric acid ranging from pH 3.0 to pH 3.7. In
the case of both NAC and citric acid at pH < pKa or pKa1, no viable cells
Fig. 2. The killing efficacy of citric acid differs at concentrations between its three pKa values when P. aeruginosa mucA biofilms are treated with different con-
centrations of citric acid. (a) Citric acid at pH 3 kills the bacteria in biofilms effectively. (b, c, d) Citric acid at pH 3.6, 3.8 and 4 kills bacteria within biofilm colonies
but does not kill cells at the periphery of the microcolonies. (e) Citric acid at pH 5 is ineffective in killing the biofilm bacteria. (f) The percentage of live and dead
bacteria when treated with citric acid at pH 3, 3.6, 3.8, 4 and 5. (g) CFU per mL of P. aeruginosa mucA biofilms treated with citric acid at pH 2.5, 3.7 and pH 5.6.
Asterisks indicate statistically significant differences between pairs of values (*p < 0.05). Limit of detection is 10 CFU/mL.
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and citric acid at pH< pKa or pKa1 kill cells within 60 min of incubation.
However, at a concentration of 3.25 mg/mL citric acid (pH 3.7; between
pKa1 and pKa2), the number of planktonic bacteria that remained viable
after 3 h was the same as that of the control, albeit with an initial
decrease after 1 h.
We also compared the effect of citric acid at pH 3.7 on planktonic
bacteria in the log phase as well as in the stationary phase of growth
(Fig. 3b). The number of viable cells in the log phase and stationary phase4
of growth was 1.5  108  5  107 CFU/mL and 1.5  107  5.8  106
CFU/mL respectively after 1 h and 3.9  108  3.3  108 CFU/mL and
1.6  107  1  107 CFU/mL after 3 h of treatment. In both cases, there
were no viable cells detected after 24 h of treatment. Hence, there is a
faster decrease in the number of cells in the stationary phase compared to
the log phase culture. This confirmed that citric acid at pH between pKa1
and pKa2 kills the slow growing cells at a faster rate compared to the
metabolically active bacteria. However, further experiments need to be
performed to assess if the bacteria in the viable outer layer of biofilms inFig. 3. (a) CFU per mL of P. aeruginosa
mucA planktonic cultures in log phase
treated with NAC at pH 3 (blue squares),
NAC at pH 3.5 (red triangles), citric acid
at pH 3 (cyan diamonds) and citric acid
at pH 3.4 (green stars). When treated
with citric acid at pH 3.7 (magenta tri-
angles), which is between pKa1 and
pKa2, the planktonic bacteria were not
killed. (b) Comparison of the effect of
citric acid at pH 3.7 on planktonic bac-
teria in the log phase and in the sta-
tionary phase of growth. Asterisks
indicate statistically significant differ-
ences between pairs of values
(*p < 0.05, **p < 0.001). The limit of
detection is10 CFU/mL.
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NAC is broadly effective in killing biofilm bacteria
Although most bacteria form biofilms, their biofilm morphology and
matrix composition vary considerably [47,48]. To investigate whether
weak acid drugs has broad spectrum activity against a wide range of
bacteria, we tested the effect of a monoprotic NAC and triprotic citric
acid on K. pneumoniae, S. aureus and P. putida. These species were grown
in flow cells for 2 d to establish biofilms of more than 50 μm thickness,
which were considered to be mature biofilms in this system, based on
previous observations [49]. The biofilms were then treated with 10
mg/mL NAC or citric acid (pH 2.5) for 30 min and their viability was
assessed using the PI stain.
Before treatment with NAC or citric acid, 99 0.2%, 95 3% and 60
 31% of K. pneumoniae, P. putida and S. aureus, respectively, were
considered alive or viable, as determined by the GFP signal (Fig. 4a–c).
After treatment with NAC or citric acid, no viable K. pneumoniae or
P. putida cells could be detected in the biofilm (Fig. 4d, e, g and h). In the
case of S. aureus, 94  6% of bacteria were dead after NAC treatment
(Fig. 4f and j), while 50  43% of bacteria appeared viable after citric
acid treatment (Fig. 4i and j).
The CFU/mL obtained from biofilms before and after treatment
showed no detectable colonies in the case of K. pneumonia and P. putida
after treatment with NAC and citric acid. S. aureus on the other hand
showed a decrease from 2  109  1.8  109 CFU/mL to 8.6  105  7.2
 105 CFU/mL and 5.4  105  2.9  105 CFU/mL when treated with
NAC and citric acid respectively (Fig. 4k). This suggests that weak acids
show broad activity against biofilms formed by the bacterial species
tested here. It should be noted that regrowth of biofilms was observed
when S. aureus treated with NAC and citric acid was left to grow for 24 h
after treatment, whereas the other species of bacteria did not show any
sign of regrowth (Supplementary Fig. 1).
NAC effectively kills antibiotic-resistant biofilm bacteria
Having demonstrated that weak acids are broadly effective in killing aFig. 4. (a–c) Representative confocal images of biofilms formed by K. pneumoniae, P.
the biofilms were treated with 10 mg/mL NAC (pH 2.5). (g–i) Green and red chann
percentage of dead and live bacteria in biofilms before and after treatment with N
treatment with NAC and citric acid. Asterisks indicate statistically significant differenc
colour in this figure legend, the reader is referred to the Web version of this article.
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range of biofilm bacteria, we propose that these compounds can be used
as an alternative drug to treat infections caused by antibiotic resistant
strains of bacteria. To test this hypothesis, we investigated the efficacy of
NAC on two clinical isolates: (i) P. aeruginosa DK1-NH57388A, a mucoid
cystic fibrosis isolate [50], and (ii) P. aeruginosa PA_D25, which is a
multidrug resistant strain [51]. It should be noted that these strains were
not GFP tagged and hence the biofilms were stained with a live-dead
reagent (SYTO9-PI) for visualisation and quantification.
For untreated P. aeruginosa biofilms (Fig. 5a and d), ~99% and 92% of
the bacteria in microcolonies were alive. When treated with 10 mg/mL
NAC (pH 2.5) for 30 min and again stained with PI, bacteria within these
colonies displayed a red signal. Fig. 5b and e show an overlay of the live
and dead stains. After treatment with NAC, the bacteria initially stained
with SYTO9 were killed in biofilms formed by both P. aeruginosa strains
(Fig. 5g). Since staining of bacteria with SYTO9 and PI before treatment
may alter the bacterial cells, experiments were also performed without
the initial staining (Supplementary Fig. 2).
The CFU/mL obtained from the two bacterial strains are shown in
Fig. 5c and f. After exposure of both strains of bacteria to 10 mg/mL NAC
(pH 2.5; pH < pKa), no viable cells could be detected by CFU determi-
nation. When treated with 3 mg/mL NAC (pH 3.3; pH ¼ pKa), the
number of viable cells decreased from 8.2  108  3.2  108 CFU/mL to
74 43 CFU/mL for P. aeruginosa DK1-NH57388A and from 3.1 109 
3  109 CFU/mL to 390  142 CFU/mL for P. aeruginosa PA_D25. Hence,
we showed that NAC is efficient in eradicating biofilms formed by cystic
fibrosis isolates as well as P. aeruginosa PA_D25, which is multidrug
resistant. While this suggests that weak acids are effective irrespective of
drug resistance or sensitivity, further work would be needed to verify this
with a range of different species.
Low pH of drugs is non-toxic to a human cell-line
To treat biofilm-related infections, the weak acid concentration has to
be such that the pH is less than the pKa. For example, the effective
concentration of NAC has to be less than 3.3. To ascertain whether this
pH range is toxic to human cells or tissue, we assayed HeLa cells grown in
96 well plates to a confluence of approximately 80% and exposed to NACputida and S. aureus bacteria expressing GFP. (d–f) Green and red channels after
els after the biofilms were treated with 10 mg/mL citric acid (pH 2.5). (j) The
AC and citric acid. (k) CFU per mL of the bacteria in biofilms before and after
es between pairs of values (**p < 0.001). (For interpretation of the references to
)
Fig. 5. Representative confocal images of micro-
colonies formed by (a) P. aeruginosa strain DK1-
NH57388A, a mucoid cystic fibrosis isolate and (d)
P. aeruginosa PA_D25, an antibiotic resistant strain,
before treatment with NAC. The biofilms were
stained with the live-dead reagents. (b, e) After
treatment with 10 mg/mL NAC (pH 2.5), live-dead
staining showed that majority of the bacterial cells
in the colony were killed. (c, f) The CFU per mL of the
bacteria treated with NAC at pH 2.5 and 3.3. The
limit of detection is 10 CFU/mL. (g) The percentage
of live and dead cells before and after treatment with
NAC.
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(pH 3.8 to 3,  pKa value) for 15 min. A significant percentage of HeLa
cells remained viable when treated with NAC at concentrations less than
3 mg/mL (pH 3.3), as measured using Presto Blue (Fig. 6a). NAC treat-
ment from 2.4 mg/mL (pH 3.5) to 3 mg/mL (pH 3.3) was effective in
killing P. aeruginosa biofilm cells (Fig. 6b), while remaining non-toxic to
human cells. Hence, we propose that weak acids can be safely used to
treat bacterial infections in humans/animals provided the pH is main-
tained between 3.5 and 3.3.
Conclusions
Here we investigated the efficacy of weak acids in eradicating bio-
films, especially those formed by antibiotic resistant bacteria, as well as
how the efficacy varies with proticity of the weak acids. We found that
the undissociated form of monoprotic weak acids can completely kill
bacteria in biofilms. Triprotic acid behaved differently between its three
pKa values, with complete eradication of biofilm at pH < pKa1. At pH
between pKa1 and pKa2, citric acid was effective in killing bacteria at the
core of the biofilm colonies, but was ineffective in killing the cells at the
biofilm periphery. We also showed that weak acids have a broad spec-
trum of activity and killed bacteria in biofilms formed by K. pneumoniae,
P. putida, S. aureus, as well as antibiotic-resistant and cystic fibrosis iso-
lates. As low pH of the acid was shown to be non-toxic to a human cell6
line, weak acids could represent an alternative therapeutic agent against
antibiotic resistant biofilm infections.
Materials and methods
Flow chamber
Poly(dimethyl siloxane) (PDMS) flow cells were fabricated from a 3D
printed stamp, using a Sylgard 184 kit (Dow Corning, UK). The flow cell
had a straight channel with dimensions of 0.2 cm  0.5 cm  3 cm
(height  width  length) [6]. PDMS monomer and the curing agent
were mixed in a 10:1 ratio (w/w) and this mixture was placed in a vac-
uum chamber for 1 h to remove air bubbles trapped during mixing. The
mixture was then slowly poured into the mold and left at room temper-
ature for 24 h after which it was incubated at 70 C for 1 h. Once the
PDMS cooled, it was removed from the mold, oxygen-plasma treated and
bonded to a glass coverslip. Inlet and outlet holes of 1 mm diameter were
created using Uni-CoreTM punchers (Sigma-Aldrich, St. Louis, MO, USA)
before bonding.
Flow system
Continuous flow of nutrients was provided by a simple, gravity fed
system, which comprised of an inverted conical flask (1 L), with a one-
Fig. 6. (a) Viability of HeLa cells treated with different concentrations of NAC.
The viable cells fluoresced when incubated with Presto Blue for 30 min. The
cells not treated with NAC were labelled as media and normalized to 100%. (b)
Biofilms treated with 2 mg/mL NAC (pH 3.8) was not killed whereas the ones
treated with 2.4 mg/mL (pH 3.5) and 3 mg/mL (pH 3.3) was killed. (For
interpretation of the references to colour in this figure legend, the reader is
referred to the Web version of this article.)
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inserted into the rubber stopper to allow for adjustment of the flow rate.Biofilm formation
An alginate-overproducing P. aeruginosa mucA strain [52], P. putida
OUS82 [53], S. aureus 15981 [54], K. pneumoniae KP1 [49], P. aeruginosa
DK1-NH57388A [50] and P. aeruginosa PA_D25 [51] were used for the
study. Fluorescently-tagged strains were constructed by the insertion of a
mini-Tn7-enhanced green fluorescent protein (eGFP)- Gmr cassette as
previously described [55]. Overnight cultures of these strains were
grown in Luria-Bertani broth (5 g/L NaCl, 5 g/L yeast extract, 10 g/L
tryptone) at 37 C under shaking conditions (200 rpm). The overnight
cultures were diluted to an optical density at 600 nm (OD600) of 0.4, and
350 μL was injected into the flow cell and incubated for 1 h to allow the
bacteria to attach to the glass surface. After the initial attachment, 10%
LB medium was supplied to the biofilm at a flow rate of 100 μL/min. The
biofilms were then allowed to grow for 2 d.Treatment, staining and imaging
N-acetyl cysteine, acetic acid, citric acid and formic acid were pur-
chased from Sigma-Aldrich. Weak acids were prepared using 10% LB,
100% LB or PBS buffer. The pH of weak acids at a particular concen-
tration can be different depending on the solvent used due to their
buffering action. NAC at concentrations 10, 2 or 0.1 mg/mL (pH 2.5, 3
and 5 respectively) and citric acid at 2, 0.6, 0.5, 0.4 or 0.1 mg/mL (pH 3,
3.6, 3.8, 4 and 5) prepared using 10% LB medium was used for the
treatment of biofilms. Acetic and formic acids were diluted using 10% LB
medium to obtain a pH of 3 or 5. Ten or 5mg/mL (pH 3 and 3.5) NAC and
10, 5 or 3.25 mg/mL (pH 3, 3.4 and 3.7) citric acid prepared using 100%7
LB was used to treat planktonic cultures. Two to 5 mg/mL (pH 3.8 to 3)
NAC was prepared using PBS buffer for treatment of HeLa cells.
A live-dead viability kit containing SYTO9 and propidium iodide (PI)
(Thermo Fisher Scientific, USA) was used to stain biofilms. The GFP
tagged biofilms were stained with 0.3% (v/v) of PI for 20 min to visualize
the presence of dead bacteria or eDNA in biofilms before treatment with a
drug. The stain was then flushed out and biofilms imaged. The biofilms
were treated with the drug for 30 min after which the drug was flushed
out with 10% LB. The treated biofilms were again stained with PI stain to
visualize the dead bacteria after treatment. The biofilm bacteria that
were not GFP tagged were stained with both SYTO9 and PI at concen-
trations of 0.3% (v/v) before treatment.
Imaging of the biofilms was performed using a Fluoview 1000
confocal microscope (Olympus Japan) with a 20 or 60 oil immersion
objective. Two image channels were acquired for each stack using GFP
488 and Alexa 594 excitation filters. The number of z-stacks depended on
the height of the colonies.
At least three independent repeats of all the experiments were
performed.CFU counts of planktonic culture and biofilms
P. aeruginosa mucA planktonic cultures were grown in LB medium to
an optical density at 600 nm (OD600) of 0.4. This culture was then diluted
10 times with LB containing 10 and 5 mg/mL NAC (pH 3 and 3.5), 10, 5
and 3.25 mg/mL citric acid (pH 3, 3.4 and 3.7). The number of colony
forming units per mL (CFU/mL) were recorded after 0, 1 and 3 h.
To measure the CFUs of biofilm bacteria after treatment with drugs,
biofilms were grown in open flow cells as described previously [6], and
treated with NAC. The flow cells were then opened, the biofilms scraped
out and diluted in 10% LB medium, vortexed to homogenize the bacteria
in the solution and plated on LB agar plates after a serial dilution.HeLa cells culture and viability detection
HeLa cells were cultured in Dulbecco’s Modified Eagle Medium
(DMEM) (Thermofisher Scientific) in 96 well plates to 80% confluence.
NAC solutions ranging from 2 to 5 mg/mL were prepared using PBS
buffer. The corresponding pH ranged from 3.8 to 3, respectively. The
HeLa cells were rinsed with PBS and incubated with NAC for 15 min,
after which the cells were again rinsed with PBS to remove the NAC and
the incubated with Presto Blue for 30 min. The viable cells change the
Presto Blue solution into a fluorescent product, which is detected from
the absorbance measurement.
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